The Potential of the CNS As a Reservoir for HIV-1 Infection: Implications for HIV Eradication

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2015 Apr 15

PMID 25869939

Citations 42

Authors

Alessandro F Fois

Bruce J Brew

Affiliations

Soon will be listed here.

Abstract

The ability of HIV-1 to establish latent infection is a key obstacle to its eradication despite the existence of effective antiretroviral drugs. The brain has been postulated as a reservoir for latent infection, but its role in HIV persistence remains unclear. In this review, we discuss the evidence surrounding the role of the central nervous system (CNS) as a viral reservoir and the potential challenges this might present in eradicating HIV. The strategies for eradication of HIV and their application to latent CNS infection are explored. Finally, we outline new developments in drug delivery and new therapeutic modalities designed to target HIV infection in the CNS.

Citing Articles

Unveiling neuroimmunology profile of immunological non-responders in HIV: a multimodal MRI approach.

Zhang Y, Ji J, Zheng L, Cai M, Sun G, Ma Y Front Immunol. 2024; 15:1452532.

PMID: 39735540 PMC: 11671397. DOI: 10.3389/fimmu.2024.1452532.

Disparate trajectories of cognitive aging among American Indian and Alaskan Native people with and without HIV.

Savin M, Byrd D, Cysique L, Rourke S, Verney S, Radford K Neuropsychology. 2024; 38(6):540-556.

PMID: 39023931 PMC: 11479638. DOI: 10.1037/neu0000950.

Ionic Liquid Coating-Driven Nanoparticle Delivery to the Brain: Applications for NeuroHIV.

Hamadani C, Mahdi F, Merrell A, Flanders J, Cao R, Vashisth P Adv Sci (Weinh). 2024; 11(23):e2305484.

PMID: 38572510 PMC: 11186118. DOI: 10.1002/advs.202305484.

Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture.

McMullan H, Gansemer B, Thayer S Front Pharmacol. 2024; 15:1369757.

PMID: 38533258 PMC: 10963620. DOI: 10.3389/fphar.2024.1369757.

Ionic Liquid Coating-Driven Nanoparticle Delivery to the Brain: Applications for NeuroHIV.

Hamadani C, Mahdi F, Merrell A, Flanders J, Cao R, Vashisth P Res Sq. 2023; .

PMID: 36824802 PMC: 9949257. DOI: 10.21203/rs.3.rs-2574352/v1.

References

Gray L, Turville S, Hitchen T, Cheng W, Ellett A, Salimi H . HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PLoS One. 2014; 9(2):e90620. PMC: 3938779. DOI: 10.1371/journal.pone.0090620. View

Clements J, Gama L, Graham D, Mankowski J, Zink M . A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS. 2011; 6(1):37-42. PMC: 3215305. DOI: 10.1097/COH.0b013e3283412413. View

Takahashi K, Wesselingh S, Griffin D, McArthur J, Johnson R, Glass J . Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol. 1996; 39(6):705-11. DOI: 10.1002/ana.410390606. View

Deng K, Pertea M, Rongvaux A, Wang L, Durand C, Ghiaur G . Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015; 517(7534):381-5. PMC: 4406054. DOI: 10.1038/nature14053. View

DiGiusto D, Krishnan A, Li L, Li H, Li S, Rao A . RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010; 2(36):36ra43. PMC: 3130552. DOI: 10.1126/scitranslmed.3000931. View

Joos B, Fischer M, Kuster H, Pillai S, Wong J, Boni J . HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A. 2008; 105(43):16725-30. PMC: 2575487. DOI: 10.1073/pnas.0804192105. View

Overton E, Sterrett S, Westfall A, Kahan S, Burkholder G, Zajac A . Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. AIDS. 2015; 28(17):2627-2631. PMC: 4338916. DOI: 10.1097/QAD.0000000000000475. View

Sharer L, Saito Y, da Cunha A, Ung P, Gelbard H, Epstein L . In situ amplification and detection of HIV-1 DNA in fixed pediatric AIDS brain tissue. Hum Pathol. 1996; 27(6):614-7. DOI: 10.1016/s0046-8177(96)90172-0. View

Valcour V, Sithinamsuwan P, Letendre S, Ances B . Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2010; 8(1):54-61. PMC: 3035797. DOI: 10.1007/s11904-010-0070-4. View

10.

Gray L, Tachedjian G, Ellett A, Roche M, Cheng W, Guillemin G . The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013; 8(4):e62196. PMC: 3628669. DOI: 10.1371/journal.pone.0062196. View

11.

Archin N, Liberty A, Kashuba A, Choudhary S, Kuruc J, Crooks A . Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012; 487(7408):482-5. PMC: 3704185. DOI: 10.1038/nature11286. View

12.

Persaud D, Gay H, Ziemniak C, Chen Y, Piatak Jr M, Chun T . Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013; 369(19):1828-35. PMC: 3954754. DOI: 10.1056/NEJMoa1302976. View

13.

Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E . Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2010; 117(10):2791-9. DOI: 10.1182/blood-2010-09-309591. View

14.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

15.

Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price R . Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014; 28(15):2251-8. PMC: 4492794. DOI: 10.1097/QAD.0000000000000400. View

16.

Dinoso J, Rabi S, Blankson J, Gama L, Mankowski J, Siliciano R . A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol. 2009; 83(18):9247-57. PMC: 2738256. DOI: 10.1128/JVI.00840-09. View

17.

Chun T, Davey Jr R, Ostrowski M, Justement J, Engel D, Mullins J . Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med. 2000; 6(7):757-61. DOI: 10.1038/77481. View

18.

Queen S, Mears B, Kelly K, Dorsey J, Liao Z, Dinoso J . Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol. 2011; 85(17):9167-75. PMC: 3165835. DOI: 10.1128/JVI.00366-11. View

19.

Carroll-Anzinger D, Al-Harthi L . Gamma interferon primes productive human immunodeficiency virus infection in astrocytes. J Virol. 2005; 80(1):541-4. PMC: 1317538. DOI: 10.1128/JVI.80.1.541-544.2006. View

20.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View